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Solid tumors comprise cancer cells and different supportive stromal cells, including mesenchymal stem cells
(MSCs), which have recently been shown to enhance tumor growth and metastasis. We provide new mechanistic
insights into how bone marrow (BM)–derived MSCs co-injected with Lewis lung carcinoma cells promote tumor
growth and metastasis in mice. The proinvasive effect of BM-MSCs exerted on tumor cells relies on an
unprecedented juxtacrine action of BM-MSC, leading to the trans-shedding of amphiregulin (AREG) from the tumor
cell membrane by tumor necrosis factor-α–converting enzyme carried by the BM-MSC plasma membrane. The
released soluble AREG activates cancer cells and promotes their invasiveness. This novel concept is supported by
the exploitation of different 2D and 3D culture systems and by pharmacological approaches using a tumor
necrosis factor-α–converting enzyme inhibitor and AREG-blocking antibodies. Altogether, we here assign a new
function to BM-MSC in tumor progression and establish an uncovered link between AREG and BM-MSC.
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Cancers have long been considered the consequence of DNA
mutations, particularly in oncogenes and tumor-suppressive genes
that affect cell proliferation and survival [1,2]. However, these cancer
cell– and genome-centered models have overlooked the complex
nature of the tumoral tissue. Indeed, cancer cells are embedded in a
tumor stroma composed of extracellular matrix and stromal cells, such
as endothelial and lymphatic cells, immune and inflammatory cells,
and (myo)fibroblasts [3]. The complex cross talk between tumor and
stromal cells influences tumor cell behavior and facilitates metastatic
dissemination to distant organs [1,4–7]. Cancer cells themselves are
also able to alter the adjacent tissue to establish a permissive and
supportive environment for tumor progression [3].
Fibroblastic-like cells can be derived from the activation of resident
cells or the recruitment of bone marrow (BM)–derived mesenchymal
stem cells (MSCs) [7,8]. MSCs are now recognized as an important
source of carcinoma-associated fibroblasts (CAFs) [4]. MSCs are
multipotent progenitor cells characterized by their capacity for
self-renewal and differentiation into chondrocytes, osteocytes,
adipocytes, fibroblasts, and other cell types [5,9]. Growing evidence
has shown the crucial contribution of MSCs to malignant progression.Depending on the system used, MSCs have been shown to favor tumor
growth and cancer metastasis by promoting angiogenesis, increasing the
invasive properties of tumor cells, or preventing tumor cell recognition
by the immune system [6,10–12]. On the other hand, few studies have
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The cross talk between cancer cells and MSCs occurs mainly through
paracrine signaling mechanisms that are mediated by the secretion of
soluble factors, including cytokines, chemokines, growth factors, and
proteases [6,12,15–17]. Among these factors, the epidermal growth
factor receptor (EGFR) ligand family plays a crucial role.
Amphiregulin (AREG) is one of the seven members of the EGFR
ligand family (including HB-EGF, EGF, betacellulin, TGF-alpha,
neuregulin, and epiregulin). AREG interacts exclusively with EGFR
(also named HER1 or c-Erb1) but with less affinity than EGF and
activates subsequent signaling pathways such as MAPK, PI3/Akt, and
STAT3. AREG is expressed as a transmembrane precursor, which is
activated through a proteolytic cleavage that involves tumor necrosis
factor-α–converting enzyme (TACE), which is also referred to as
ADAM17 [18] and is a transmembrane protease implicated in the
shedding of many substrates [19]. This shedding gives rise to various
forms of AREG, either secreted or membrane bound, which act in an
autocrine, paracrine, or juxtacrine manner on cells in the direct
neighborhood or at distant sites [20,21]. Several studies report protumoral
and proinflammatory roles of TACE [22].
In this study, we found that juxtacrine-mediated interactions
between BM-MSCs and Lewis lung carcinoma (LLC) cells stimulate
the in vivo and in vitro proliferative and invasive properties of cancer
cells. BM-MSCs shed AREG from cancer cell membrane through
TACE activity, as assessed by a pharmacological approach. The
functional implication of AREG in cancer cell invasion is supported by
its inhibition with AREG-blocking antibodies. We are thus assigning a
novel function to BM-MSC that relies on the shedding of AREG at the
surface of cancer cells, thereby promoting cancer invasion.
Material and Methods
Animal Studies
All animal experiments were conducted in accordancewith the guidelines
of the local ethical committee of the University of Liège (Belgium).
Metastasis Experiment. Six- to eight-week-old femaleC57BL/6mice
(Janvier Laboratories, Saint-Berthevin, France) were subcutaneously
injected (in the two flanks) with LLC cells (1 × 105) alone or with
BM-MSCs (5 × 105). Tumor growth was evaluated by measuring
luciferase bioluminescence at days 7, 9, 12, and 14 after injection using the
bioluminescent IVIS imaging system (Xenogen-Caliper,Hopkinton,MA).
At day 14 after cell injection, the primary tumor masses were excised, and
metastases were monitored in vivo weekly by using the bioluminescent
imaging system. At 35 days after injection, themicewere sacrificed, and the
organs (lung, liver, ovary, kidney, intestine, and pancreas) were checked
ex vivo for metastatic colonization through bioluminescence detection.
Tumor Kinetic Experiment. The mice injected as described above
were sacrificed at 7, 9, 12, and 14 days postinjection. For the visualization
of functional vessels, 200 μl of FITC-dextran (2.5 mg/ml in PBS) (Sigma
Aldrich, St Louis, MO) was intravenously injected 3 minutes before
sacrifice. Tumors were weighed, and histopathological analyses were
performed as described below.
Measurement of Hemoglobin Content
Tumors resected at day 14 postinjection were lyophilized, and the
hemoglobin content was determined by using Drabkin’s reagent
according to the manufacturer’s instructions (Sigma Aldrich). The
amount of hemoglobin was normalized to the weight of the lyophilized
tumor. The data presented are those of two independent experiments.Cell Lines, Recombinant Proteins, and Blocking Antibodies
The luciferase-expressing LLC (Luc-LLC) cell line of the C57BL/6
background was purchased from Caliper Lifesciences (Xenogen-
Caliper). Luc-LLC cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Gibco Invitrogen Corporation, Paisley, United
Kingdom) supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 2 mM glutamine, 100 UI/ml penicillin/streptomycin,
and 1 mg/ml geneticin [selective antibiotic (Serva GmbH, Heidel-
berg, Germany)] and maintained in a humidified incubator at 37°C
in a 5% CO2 atmosphere. We used commercially available,
recombinant AREG (R&D Systems, Minneapolis, MN); TAPI-0
(Calbiochem, San Diego, CA), which is an inhibitor of TACE; and
AG1478 (Calbiochem), an inhibitor of EGFR.
Mesenchymal Stem Cell Isolation and Characterization
MSCs were isolated from the BM of either C57BL/6J or transgenic
mice that were heterozygous for the enhanced green fluorescent
protein (eGFP) under the control of the β-actin promoter C57BL/
6-Tg(ACTbEGFP)10sb (Jackson Laboratories, Bar Harbor, ME).
Mouse tibiae and femurs were carefully cleaned and crushed in a
mortar, and the BM was recovered with phosphate-buffered saline
(PBS) containing 2% FBS and 1 mM EDTA. Mononuclear cells were
isolated using Ficoll (GE Healthcare Bioscience AB, Uppsala,
Sweden). Cells were rinsed twice with PBS and then seeded in
complete Mesencult medium (Stem Cell Technologies, Grenoble,
France). After 3 days of culture at 37°C, nonadherent cells were
removed, and the adherent layer was cultured until it reached 70% to
80% confluence. The mesenchymal cell population was further
purified by negative selection with the “mouse hematopoietic
progenitor stem cell enrichment set” (BD Bioscience, Berdford,
MA, USA). The MSC phenotype was characterized by immuno-
staining and flow cytometry (FACS) analysis. Osteogenic and
adipogenic differentiation assays were also performed on the MSCs,
as previously described [23].
Culture Conditions and Preparation of Conditioned Medium
LLC cells were cultured alone (monoculture), with a direct cell mixture
of BM-MSCs (direct co-culture), or in a Transwell chamber (pore 0.4
μm; Greiner BioOne, Frickenhausen, Germany) in which the two cell
types were separated by a semipermeable membrane (1:5 ratio) (indirect
co-culture). Two days after cell seeding, the cells were starved for 1 hour
with serum-free DMEM, and the medium was replaced with fresh,
serum-free DMEM. After 24 hours, the conditioned medium (CM) was
collected, centrifuged at 1000g for 10 minutes, and concentrated 10×
with Amicon Ultra Centrifugal Filters 10K (Millipore, Cork, Ireland).
CM aliquots were stored at −20°C until use.
Proliferation Assay
For the proliferation assays, BM-MSC (6 × 104 cells/well) and
Luc-LLC cell (3 × 104 cells/well) monocultures, direct co-cultures, or
indirect co-cultures were seeded in 24-well plates in DMEM containing
2% FBS. After 3 days, 150 μg/ml of luciferine (Promega, Madison,WY)
was added to each well, and plate images were collected for 10 seconds to
1 minute using the IVIS imaging system (Xenogen-Caliper). Photons
emitted from tumor cells were quantified using the Living Image software
(Xenogen-Caliper). The suitability of this assay was assessed by seeding an
increased number of LLC cells in the presence or absence of BM-MSCs,
leading to an output signal that was directly correlatedwith the number of
seeded cells.
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Multicellular spheroids were generated by seeding LLC cells (1 × 103)
alone or with BM-MSCs (5 × 102) in each well of a nonadherent,
round-bottomed plate (Greiner BioOne) in DMEM containing 2% FBS
and 0.24% high-viscosity methyl cellulose (Sigma Aldrich). After 24
hours of culture, spheroids (maximum 8/well) were collected, embedded
in type I collagen gels (1.25 mg/ml; BD Biosciences) in 24-well plates,
andmaintained in 2%FBS-DMEMat 37°C for 24 hours. In some assays,
collagen gels (1.25 mg/ml, BD Biosciences) were preincubated before
spheroid embedding with the following compounds: a neutralizing
anti-AREG antibody (3 μg/ml, R&D Systems), a normal goat IgG
control (3μg/ml, R&D Systems), an EGFR inhibitor, AG1478 (20 μM,
Calbiochem), and a TACE inhibitor, TAPI-0 (10 μM, Calbiochem)
Cells were examined under a Zeiss Axiovert 25microscope equippedwith
an Axiocam Zeiss camera and KS 400 Kontron image-analysis software
(Carl Zeiss Microscopy, Zaventem, Belgium).
Image Analysis and Computerized Quantification
Image processing and measurements were implemented using the
image analysis toolbox of Matlab 7.9 (Mathworks, Natick, MA)
according to the following steps. Morphological filters [24] were first
applied to correct uneven illumination in the collagen background
and to eliminate noise. Cells were then segmented using an automatic
threshold [25]. The convex envelope, defined as the minimal convex
polygon that contained the whole spheroid, was automatically
determined. Finally, the convex envelope area, defined as the number
of pixels belonging to the convex envelope multiplied by the pixel size
(in mm2), was measured for each spheroid.
RNA Extraction and Reverse Transcription–Polymerase Chain
Reaction (RT-PCR)
Total RNAs from BM-MSCs and LLC cells were extracted using
the High Purity RNA isolation kit (Roche, Mannheim, Germany)
according to the manufacturer’s protocol. RT-PCR was performed on
10 ng of total RNA using an amplification kit (GeneAmp
Thermostable rTth Reverse Transcriptase RNA PCR Kit; Roche).
The RT-PCR products were resolved in 10% acrylamide gels and
analyzed with a fluorescence imager (LAS-4000; Fujifilm, Tokyo,
Japan) after staining with Gel Star (Cambrex, East Rutherford, NJ).
The gene expression levels were measured as the ratio between
expression values and internal 28S. Statistical significance of
differences between the observed values was evaluated using the
Mann-Whitney test.
Western Blotting
Cells or tumors were lysed for 30 minutes in ice-cold lysis buffer
(1% Triton X-100, 150 mM NaCl, 1% IGEPAL-CA 630, 1% Na
deoxycholate, 0.1% sodium dodecyl sulfate, complete). To achieve
homogenization, tumor extracts were placed in tubes containing
ceramic beads (Magna Lyser Green Beads; Roche) in a Magna Lyser
(Roche). Cell lysates were clarified by centrifugation at 12000 rpm at
4°C for 30 minutes and stored frozen at −20°C. The protein
concentrations were determined using the DC Protein Assay kit
(Bio-Rad Laboratories, Hercules, CA), and protein samples were
resolved on sodium dodecyl sulfate polyacrylamide gels and
subsequently transferred to polyvinylidene fluoride membranes.
The membranes were treated with blocking buffer (PBS with 0.1%
Tween-20; Merck, Darmstadt, Germany, and 1% casein; Sigma
Aldrich) for 1 hour at room temperature before overnight incubationat 4°C with primary antibodies raised against mouse AREG (1/500, goat
anti-mouse IgG; R&D Systems) or mouse TACE (1/500, rabbit
anti-mouse IgG; Millipore). After washings, the membranes were
incubated for 1 hour with secondary horseradish peroxidase antibodies
(1/3000, donkey anti-goat/HRP; Santa-Cruz Biotechnology, Inc., Santa
Cruz, CA, or 1/2000, goat anti rabbit/HRP;DakoCytomation,Glostrup,
Denmark), and proteins were detected by chemiluminescence using an
enhanced chemiluminescence kit (Perkin Elmer Life Sciences, Boston,
MA) according to the manufacturer’s instructions. Subsequent detection
of actin (rabbit anti-actin; Sigma Aldrich) was performed on the same
filters as the loading control.
Cytokine Array and AREG ELISA
A “Proteome Profiler, Mouse Angiogenesis Array kit” was applied on
medium conditioned by cells according to the procedure recommended
by the manufacturer (R&D Systems). The quantification was performed
by detecting chemiluminescence (LAS-4000, Fujifilm). For a specific
dosage of AREG, aDuoSet ELISADevelopment kit (R&DSystems) was
used following the manufacturer’s instructions.
TACE Activity Assay Using a Fluorescence Resonance Energy
Transfer (FRET) Peptide
The TACE activity level was assessed using a peptide-based FRET
assay and a peptide purchased from Peptides International (Louisville,
KY) as substrate: Abz-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-
Dap(Dnp)-NH2. Upon cleavage by TACE, the fluorescence of Abz
(2-aminobenzoyl), which was quenched by Dnp (2,4-Dinitrophenyl),
was recovered andmonitored at λex = 320 nm and λem = 420 nm. For this
assay, LLC cells and/or BM-MSCs (1:5 ratio) were incubated in a 96-well
plate in DMEM containing 2% FBS. After 24 hours, the FRET peptide
was added (10 μM) to each well. DMEM containing 2% FBS without
cells was used as a control. The fluorescence was monitored every 30
minutes during 2 hours (SpectraMaxi3; Molecular Devices, Obergausen,
Deutschland).
Immunohistochemistry
The immunohistochemical analyses were performed on paraffin
sections using anti-GFP antibody (Abcam, Cambridge, United
Kingdom) to stain GFP-expressing BM-MSCs and anti-FITC
antibody (Roche) to detect functional vessels (dextran/FITC). Virtual
images were acquired using the fully automated, digital microscopy
system dotSlide (BX51TF; Olympus, Aartselaar, Belgium) coupled
with a Peltier-cooled, high-resolution digital color camera (1376 ×
1032 pixels; XC10; Olympus). The images of the whole tissue
sections were digitized at high magnification (×100), producing
virtual images with pixel sizes of 1.510 μm. On these digital images,
vessels were drawn manually and transformed to obtain a binary
image in which pixels representing vessels had intensity equal to 1 and
those corresponding to the background intensity had intensity equal
to 0. The number of vessels on those binary images was measured
automatically. The results are expressed as the unity of the area of
tumor tissue. Image analysis was conducted using the Matlab 7.9
software (Mathworks).
TACE Knockdown
BM-MSCs were transfected with LNA-GapmeRs (Exiqon,
Vedbaek, Denmark) targeting one common sequence of three
variants of TACE: 5 -GAGTTACAGAGTTGA-3 , referred as
“Gap TACE”. As negative control, a nonhomologous sequence
Neoplasia Vol. 17, No. 7, 2015 Juxtacrine Effect of MSC on Lung Carcinoma Cells Carnet et al. 555(“Gap CTRL”) was designed: 5 -AACACGTCTATACGC-3 . Cells
were transfected by using interferin according to the manufacturer’s
instructions (Polyplus, Leuven, Belgium). TACE mRNA expression
and enzymatic activity were analyzed 72 hours after transfection.
Statistical Analysis
Data were analyzed with GraphPad Prism 5.0 (San Diego, CA).
The appropriate test was used [linear regression, chi squared,
Student’s t test or Mann-Whitney (for non-Gaussian distribution)]
to determine the significance (P b .05) of differences between
experimental groups (*P b .05, **P b .01, ***P b .001).
Results
BM-Derived MSCs Enhance tumor Growth and Metastasis
Formation In Vivo
MSCs were isolated from the BM of C57BL/6J mice or mice
expressing eGFP (C57BL/6-Tg(ACTbEGFP)10sb). Mononuclear
cells were collected using a Ficoll-Paque density gradient centrifuga-
tion. Nonadherent cells were removed after 3 days of culture in a
specific stem cell medium. After depletion through magnetic cell
separation of CD45- and CD11b-positive cells, BM-derived cells
were characterized using flow cytometry (FACS) and differentiation
assays. Those cells expressed the surface marker profile typical for
MSC: SCA-1 and CD106. Furthermore, we confirmed the negativity
for CD45 and CD11b, and a low positivity for CD34 [23]. After
culture under adipogenic and osteogenic differentiation conditions,
cells were stained using red oil or alizarin red to confirm their
differentiation potential. The accumulation of intracellular lipid
droplets and the deposition of extracellular calcium phosphate were
observed. Based on their phenotype and the multilineage differen-
tiation potential, cells isolated from murine BM display the typical
features of MSC [23]. The functional impact of the heterotypic
interactions that occurred between LLC cells and BM-MSCs was
evaluated in vivo by co-injecting GFP-positive BM-MSCs and
luc-LLC cells into syngeneic C57BL/6J mice. Primary tumor growth
was followed in vivo by LLC cell luminescence signal quantification
using the in vivo imaging system IVIS 200 (Figure 1A). Mice
co-injected with LLC cells and BM-MSCs exhibited accelerated tumor
growth compared with mice injected with LLC cells alone (Figure 1B).
This led to a two-fold increase in tumor volume at day 14 (Figure 1C).
At this time point, the primary tumors were removed, and the
emergence of metastases was quantified. At day 35, the incidence of
lung metastases was also higher in mice co-injected with LLC cells and
BM-MSCs (Figure 1, D–F). The injections with BM-MSCs alone did
not result in tumor formation (data not shown).
A kinetic study was conducted to investigate the fate of BM-MSCs
within LLC tumors after 7, 9, 12, or 14 days. The number of injected
BM-MSCs observed in the tumor stroma decreased drastically over time,
and only few GFP+ BM-MSCs were still detected at day 14 and are part
of the initial injected cells (Figure 2A). Interestingly, in our model, the
presence of BM-MSCs did not affect functional blood vessel formation, as
assessed by FITC-dextran detection of blood endothelial cells and
hemoglobin content measurement (Figure 2, B and C).
BM-MSCs Increase LLC Cell Proliferation and Invasion
In Vitro
Taking advantage of the luciferase expression by LLC cells, the
proliferation of LLC cells was evaluated by bioluminescence detection
after luciferin administration. Three conditions were tested: 1) LLCcells alone, 2) LLC directly co-cultured with BM-MSCs, and 3)
co-culture of LLC cells separated from BM-MSCs by a semiperme-
able membrane to avoid direct cell–cell contacts (Figure 3A). In direct
2D co-cultures, the LLC cell number was significantly increased after
72 hours of culture, whereas tumor cell proliferation was not affected
in indirect co-culture conditions (Figure 3B). In a 3D spheroid
invasion assay, LLC cell invasive properties were stimulated when tumor
cells were mixed with BM-MSCs compared with the invasion of LLC
cells as monospheroids (Figure 3C). The use of GFP-expressing
BM-MSCs in this assay demonstrated that the migrating cells were
LLC cells rather than BM-MSCs (Figure 3C). Indeed, GFP-positive cells
remained inside the spheroid, whereas LLC cells were able to spread out
and invade the surrounding type I collagen matrix.
AREG Shedding Requires a Contact Between LLC Cells and
BM-MSCs
To examine the molecular mechanism underlying BM-MSC–
mediated promotion of tumor invasiveness, we carried out
monocultures of each cell type, and direct or indirect co-cultures of
LLC cells and BM-MSCs (Figure 4A). The media conditioned by
these different cultures were screened for a panel of cytokines,
chemokines, and growth factors using a protein array. In most cases,
the resulting levels of secreted proteins reflected the additive
production of each cell type cultured alone. Interestingly, we noticed
that AREG amount was three times higher in direct co-cultures than
in monocultures. Moreover, close physical contacts between LLC
cells and BM-MSCs were required to stimulate AREG secretion
because no variation in AREG amount was observed in indirect
co-cultures (Figure 4B).
AREG regulation was next analyzed at the mRNA and protein
levels using RT-PCR and Western blot analyses, respectively. AREG
mRNAs were mainly expressed by LLC cells, and their levels were
significantly increased upon direct co-culture with BM-MSCs
(Figure 4C). Whereas the AREG protein level was not modulated
in the cell extracts of direct co-cultures (Figure 4C), the secreted form
of AREG was increased in the medium conditioned by direct
co-cultures, but not by indirect co-culture, confirming the
importance of close cell–cell contacts (Figure 4D). Consistently,
ELISA analyses revealed a three-fold increase in the secretion of
AREG in conditioned media of direct co-cultures compared with that
observed in monocultures or indirect co-cultures (Figure 4E). These
data suggest that BM-MSCs enhanced AREG secretion, likely
through a posttranslational mechanism, which could rely on shedding
of the proform into its soluble form. The modulation of AREG
production that was observed in vitro was confirmed in vivo by
Western blotting performed on tumor extracts (Figure 4F). Interestingly,
the AREG contents were increased in tumors induced by the
LLC+BM-MSC mixture compared with those induced by the LLC
cell injection alone.
AREG Shed from LLC Cells Contributes to LLC Cell Invasion
The functional consequence of AREG production on cancer cell
invasion was next evaluated in vitro in multicellular LLC spheroids
invasion assay treated with increasing concentrations of recombinant
AREG (recAREG). A high concentration of recAREG (200 ng/μl)
stimulated the invasion of LLC cells (Figure 5A). Similarly, the
medium conditioned by LLC cells directly co-cultured with
BM-MSCs, containing high amount or AREG as assessed by
ELISA, enhanced LLC cell sprouting from the spheroid. Notably,
Figure 1. MSCs enhance tumor growth and metastasis formation.Luc-LLC cells (1 × 105) were subcutaneously injected into C57BL/6J
mice in both flanks in the absence (LLC) or presence of BM-MSCs (5 × 105) (LLC+MSC). Representative data from three independent
experiments are shown. (A) In vivo bioluminescent signal of the primary tumors at day 14 post cell injection (n = 17 per group).
(B) Quantification of the luminescent signal as a function of time after cell injection (n = 17 per group; linear regression ***P b .001).
(C) Weights of primary tumors resected at day 14 (n= 17 per group; Student’s t test ***P b .001). (D) In vivo bioluminescent signal of lung
metastases at day 35. (E) Representative ex vivo bioluminescent signal of lungs resected from mice at day 35. (F) Statistical analysis of
metastasis incidence at day 35 (chi-square test **P b .01).
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antibody and not by a control antibody (Figure 5B). Moreover, the
proinvasive effect of BM-MSCs on LLC cells was abrogated by the
incubation of heterospheroids (LLC+MSC) with AG1478 (20 μM), a
specific inhibitor of EGFR (Figure 5C).
TACE Produced by BM-MSCs Is Necessary to Increase AREG
Secretion by LLC
TACE is the main protease implicated in AREG shedding [26].
We thus investigated how this protease was involved in the shedding
of AREG induced by BM-MSCs. LLC cells and BM-MSCs both
expressed TACE mRNAs, but no transcriptional modulation was
observed when BM-MSCs were co-cultured with LLC cells
(Figure 6A). Using Western blotting, we detected two forms of
TACE: a pro-TACE species of 130 kDa and activated TACE forms of
80 kDa, corresponding to glycosylated and nonglycosylated forms.Although no modulation of these two forms was observed in vitro,
increased amounts of active TACE were detected in vivo in xenografts
generated by LLC+BM-MSC mixture injection compared with LLC
tumors (Figure 6, B and C). The activity of TACE was next analyzed
in vitro by FRET to determine whether the detection of active TACE
by Western blot correlates to proteolytic activity at the cell surface.
Cells were incubated with a FRET peptide, which is a specific
substrate for TACE. Upon hydrolysis by TACE, a fluorescent signal
proportional to TACE activity is emitted. Little TACE activity was
observed in LLC cells. However, higher TACE activity was detected
in monoculture of BM-MSCs, and upon direct co-culture of
LLC+BM-MSCs, this activity was increased. In addition, the activity
of TACE was decreased using TAPI-0, an inhibitor of TACE, and
after BM-MSC transfection with anti-TACE GapmeR (Figure 6D).
As expected, the release of AREG in CM was also decreased after
TAPI-0 treatment or in co-culture with MSC Gap TACE
Figure 2. GFP-labeled BM-MSCs co-transplanted with tumor cells do not affect the vascular density within a tumor mass.Luc-labeled LLC
cells (1 × 105) were subcutaneously injected in C57BL/6J mice in the absence (LLC+; MSC−) or presence of GFP-expressing BM-MSCs
(5 × 105) (LLC+; MSC+). Primary tumors were resected at 7, 9, 12, and 14 days (D7-D14) immediately after mice injection with
dextran-FITC. (A) Immunodetection of GFP in BM-MSCs (brown) and FITC (vessels in blue) on paraffin sections of tumor tissues.
(B) Quantitative analysis of the vessel density in tumors. Data are expressed as the fold induction of the functional blood vessel (BV)
number per mm2 that was observed within the primary tumor mass. (C) Measurement of the hemoglobin content in tumors. The amount
of hemoglobin was normalized to the weight of the lyophilized tumor (n = 10 per group, ns = no statistical difference).
Figure 3. BM-MSCs promote LLC cell proliferation and invasion.LLC cells were cultured alone (LLC, monoculture) or co-cultured with
MSCs (LLC+MSC) in direct contact (direct co-culture) or separated by a semipermeable membrane in a transwell chamber (LLC/MSC,
indirect co-culture). Cells were either seeded on plastic (A, B) or embedded as spheroids in a collagen gel (C). (B) Quantitative analysis of
the luminescence intensity of Luc-LLC cells cultured for 3 days with or without BM-MSCs (Mann-Whitney: **P b .01; ***P b .001). (C) The
invasion of LLC cells in the 3D spheroid model is increased in the presence of BM-MSCs (LLC+MSC) (Mann-Whitney: ***P b .001). In the
lower panel, the spheroid is composed of LLC cells and GFP+ BM-MSCs, revealing that only cancer cells migrate into the matrix, whereas
BM-MSCs remain in the spheroid (green cells). The graph corresponds to the quantification of cell invasion.
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Figure 4. BM-MSCs enhance AREG secretion from LLC cells.LLC cells and BM-MSCs were cultured for 3 days, either alone
(monoculture), together (direct co-culture), or separated by a semipermeable membrane to avoid cell–cell contacts (indirect co-culture),
as schematically presented (A). The results presented are those of one representative assay out of at least three experiments using
different primary BM-MSC cultures. (B) The level of AREG in conditioned media is compared using a cytokine array. (C) RT-PCR analysis of
AREG mRNA expression. The results are expressed in arbitrary units corresponding to the AREG/28S ratio (Mann-Whitney: **P b .01).
(D) Western blot analysis of the AREG production in culture lysates. Production of the actin protein is included as a loading control. The
graph corresponds to the quantification of AREG production by scanning densitometry. The results are expressed as the AREG/actin ratio.
(E) Secreted levels of AREG analyzed by ELISA (right panel) and by Western blotting (left panel) on conditioned medium from LLC cells,
BM-MSCs, and direct or indirect co-cultures of LLC cells and BM-MSCs. (F) Western blot analysis of tumors resected 9 or 12 days after
injection of LLC cells with or without BM-MSCs (Mann-Whitney: *P b .05, **P b .01). Actin is used as a loading control, and data are
presented as the AREG/actin ratio.
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Figure 5. AREG present in co-cultures of MSC+LLC-conditioned media enhances tumor cell invasion in a 3D spheroid model.LLC cells
were cultured as monospheroids (LLC) without or with medium conditioned by co-cultured cells (CM LLC+MSC) or co-cultured with
BM-MSC in heterospheroids (LLC+MSC). (A) Increasing concentrations of recombinant AREG (recAREG) were added to monospheroid
cultures. (B) A control antibody (Ab Ctrl) or an anti-mouse AREG-blocking antibody (Ab AREG) was preincubated overnight at 4°C with the
conditioned medium. The stimulation of LLC cell invasion by co-culture–conditioned medium (CM LLC+MSC) is abrogated upon a
preincubation with an AREG-blocking antibody. (C) Monospheroids (LLC) and heterospheroids (LLC+MSC) were incubated with an
inhibitor of EGFR (AG1478, 20 μM) or an inhibitor of TACE (TAPI-0, 10 μM). The graph corresponds to the quantification of cell invasion
(Student’s t test: *P b .05, **P b .01; ***P b .001).
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of BM-MSC on LLC cells in a collagen gel (Figure 5C).
Discussion
Although the effects of MSCs on tumor cell invasion have been
recently described, the complex cross talk established between both
cell types is still unclear and poorly documented. We herein provide
evidence that the direct confrontation of BM-MSCs with LLC cells
significantly increases in vivo tumor growth and lung colonization aswell as in vitro tumor cell proliferation and invasion. In this study, we
identify a new juxtacrine signaling pathway involving the contact
between membrane-associated proteins present at the surface of
stromal cells (TACE) and adjacent tumor cells (pro-AREG). The
tumor-derived soluble AREG shed by the stromal TACE then acts in
an autocrine and/or paracrine manner on cancer cells and stimulates
invasiveness.
Growing evidence supports the importance of paracrine interac-
tions occurring between cancer cells and MSCs, which involve growth
Figure 6. Active TACE is increased in the presence of BM-MSCs and is responsible for AREG shedding.(A) RT-PCR analysis of TACE
expression. The results are expressed in arbitrary units corresponding to the ratio between ADAM17/28S. (B, C) Western blot analysis of
pro- and active-TACE production in vitro in culture lysates (B) and in vivo in tumors induced by LLC cells with or without BM-MSCs
(C). Actin is included as a loading control. The graph corresponds to the quantification of TACE production by scanning densitometry. The
ratio of pro-TACE/actin and active TACE/actin reveals a significant increase in active-TACE production when BM-MSCs are present in
tumors at days 9 (P= .0002) and 12 (P= .104) after injection. LLC cells and/or BM-MSCswere cultured alone or in co-cultures treated with
TAPI-0 (1 μM) or control. BM-MSCs transfected with anti-TACE or control GapmeR were also used. (D) TACE activity was evaluated by
FRET at different time points (0 to 2 hours) (linear regression: ***P b .001). (E) AREG amounts were determined in the conditioned
medium using ELISA (Mann-Whitney: *P b .05).
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and CCL5 emerged as key players [6,27,28]. The originality of our
work relies on the demonstration that juxtacrine stromal tumor cell
interactions lead to the release of soluble AREG from the tumor cell
membrane through TACE activity located at the MSC membrane.
AREG secretion was increased only when cancer cells were in direct
contact with BM-MSCs but not when they were separated by a
semipermeable membrane avoiding cell–cell contacts. The increased
AREG amounts that were detected in co-cultures are ascribed to
AREG shedding from the tumor cell surface rather than to a
transcriptional regulation of its gene expression, as assessed by
RT-PCR, Western blotting, and ELISA analyses. In in vitro assays, LLC
cell invasion was increased by the addition of medium conditioned by
BM-MSC+LLC co-cultures. Furthermore, this proinvasive effect was
abrogated by blocking antibodies targeting AREG, demonstrating the
contribution of AREG to cancer cell invasion.
AREG is overexpressed in cancerous tissues such as human colon,
stomach, breast, and pancreas [20]. The role of AREG in cancer
development and progression is supported by clinical data showing
that AREG levels are correlated with tumor progression and poor
patient survival and may serve as a prognostic biomarker, for instance,
for non–small cell lung carcinoma [29–32]. Depending on the
cellular context, AREG can exert diverse effects that affect tumor
progression such as self-sufficiency in growth signals, tissue invasion,
and evasion of apoptosis [20]. Its role in tumor initiation and/or
progression is inextricably linked to that of its receptor, EGFR. The
binding of AREG to EGFR induces autophosphorylation of the
EGFR intracellular tyrosine kinase domain leading to MEK/ERK1/2,
PI3K/AKT, and STAT3 pathway activation. Consequently, cancer
cells are endowed with proliferative, migrative, and invasive properties
through EGFR activation [20,33]. The soluble AREG form that is
shed from LLC cells acts in an autocrine or paracrine manner on
cancer cells expressing EGFR to enhance their motility and invasive
potential. This conclusion is supported by the use of an EGFR
inhibitor in the invasive assay. It is worth noting that soluble AREG
has been described as a more potent factor than membrane-anchored
AREG in mammary epithelial cells [34]. Our data are in line with
previous studies reporting that AREG increased the motility of
different cell lines, including MCF-7, SUM-149, and
MDA-MD-231 breast cancer cells [35,36]. AREG also appears to
contribute to actin rearrangement through E-cadherin redistribution
[37,38]. Furthermore, AREG can induce the expression of factors
involved in matrix degradation, such as matrix metalloproteinases
(MMP-2, MMP-9) [36,39,40]. In our spheroid invasion assay, the
MMP inhibitor Ro28-2653, which does not block TACE [41],
reduced the cell invasion from monospheroids composed of LLC cells
alone or heterospheroids composed of BM-MSCs and LLC cells to a
similar extent (data not shown). These data suggest that, in our
model, the BM-MSC-mediated effect on cancer cell invasion was
independent on MMP status. The blockade of AREG shedding by
TAPI, an inhibitor of TACE, supports the implication of TACE in
our model. Importantly, increased AREG secretion was associated
with enhanced active-TACE detection in primary tumors composed
of LLC+BM-MSC mixture as compared with primary tumors
composed of LLC cells alone. Arguing for the importance of
MSC-derived TACE, TACE activity was detected in vitro through a
specific FRET analysis in BM-MSCs but not in LLC cells. The poor
TACE activity detected in LLC cells while the enzyme was detected
by Western blot is intriguing. However, several studies have reportedthat protein levels of TACE do not directly correlate with the protein
activity [42–44]. Rather than depending on the simple removal of its
inhibitory prodomain, TACE activity seems to be readily switched
« on and off » at the cell surface [45]. The mechanism by which
TACE becomes catalytically active remains poorly understood
[26,46]. In the current work, increased TACE activity was detected
in LLC+MSC direct co-cultures as compared with monocultures.
Importantly, this activity was inhibited by TAPI. The transfection of
BM-MSCs with anti-TACE GapmeRs confirms that the increased
TACE activity relies on the BM-MSC–derived enzyme. Our data also
suggest that TACE activity on BM-MSCs requires an activation in
the presence of cancer cells through physical contact between both
cell types [46].
Our work is uncovering novel features of the complex dialogue
established between BM-MSC and tumor cells. It establishes an
unprecedented link between BM-MSC and AREG. We here assign a
novel function to BM-MSC consisting of the shedding of AREG at
the surface of tumor cells leading to proinvasive and metastatic
features. The originality of our finding relies on the observation that
AREG shedding occurs in trans, with MSC-derived TACE acting on
AREG expressed by tumor cells. A trans-shedding has been previously
reported for ADAM10 in ephrin cleavage involving only one cell type
[47]. To the best of our knowledge, this is the first report of TACE
acting in trans in a tumor cell–host cell dialogue. Although AREG
shedding has already been reported in tumor cells–(myo)fibroblast
interactions, the shed AREG was shown to act in a paracrine manner
on cancer cells [48,49]. In the present study, we define an
unprecedented link between MSC and AREG implicating a trans-
shedding of pro-AREG at the tumor cell surface. It is worth noting
that BM-MSCs within the tumor stroma can differentiate into CAFs
[12,50,51], which secrete several cytokines. In line with our data, a
recent study has reported increased expression of TACE in CAFs
extracted from human breast carcinomas compared with donor-
matched normal fibroblasts [52]. In a recent elegant study using
colorectal cancer cells [53], BM-MSCs were reported to secrete
neuregulin, another ligand of EGFR, and this was associated with
poor prognosis [53]. In contrast to our study, neuregulin was
expressed by BM-MSCs rather than by tumor cells, and cell–cell
contacts were not required to stimulate colorectal cancer progression.
Altogether, these studies shed light on the multifaceted dialogue that
occurs between BM-MSCs and tumor cells that contribute to the
tumor promotion.
In conclusion, we provide the first evidence of juxtacrine
interactions between BM-MSCs and cancer cells that increase the
release of soluble AREG from cancer cells and contribute to the
invasive properties of tumor cells. Strategies developed to interfere
with the AREG activation loop initiated by MSC and tumor cell
interactions might be of therapeutic value to prevent cancer
progression and invasion.
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